Regado shares pop as drug wins fast-track status

Regado Biosciences ($RGDO) earned a pop in its stock price this morning after it put out word that the FDA has granted fast-track status to its anticoagulant REG1. The Basking Ridge, NJ-based biotech's share price is up more than 20% on Monday morning. "We continue to believe that REG1 has the potential to become a new standard of care for anticoagulation in interventional cardiology," noted CEO David Mazzo in a statement. Release

Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.